Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
6874
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Orlando, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 913–924 of 6,874 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Completed No phase listed Observational

Mobilization and Outcomes After Venous Closure

NCT07246902
View directory record Official record
Conditions
Venous Vascular Closure, Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure Device
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 3 Interventional

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

NCT07778316
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Orlando, Florida • Grand Rapids, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Not applicable Interventional

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT06035120
View directory record Official record
Conditions
Emphysema, Pulmonary, Emphysema or COPD
Interventions
AeriSeal System
Device
Lead sponsor
Pulmonx Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Loveland, Colorado • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 1 Interventional

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT07020117
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Interventions
[225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Drug
Lead sponsor
Aktis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Terminated Phase 2 Interventional Results available

Study of the Oral Treatment MTR-601 in Cervical Dystonia

NCT06830642
View directory record Official record
Conditions
Cervical Dystonia
Interventions
MTR-601, Placebo
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Active, not recruiting Phase 3 Interventional

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

NCT04071457
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 2 Interventional

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

NCT05011383
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
High dose testosterone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Active, not recruiting Phase 3 Interventional

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731
View directory record Official record
Conditions
Age Related Macular Degeneration (ARMD)
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Terminated Phase 2 Interventional

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

NCT06079190
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
21
States / cities
San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST
Recruiting Phase 3 Interventional

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

NCT07456696
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
TSND-201, Placebo
Drug
Lead sponsor
Transcend Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:21 AM EST